Rockefeller Capital Management
AVEO

Rockefeller Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Rockefeller Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,600
Closed -$11K – 3728
2021
Q1 		$11K Buy
+1,600
New +$13.8K ﹤0.01% 2565
2019
Q4 		– Sell
-250
Closed -$2K – 2280
2019
Q3 		$2K Buy
+250
New +$1.86K ﹤0.01% 1822

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rockefeller Capital Management's AVEO Position: Q2 2021 in Review

Rockefeller Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 1,600 shares — an estimated $11K sold.

Rockefeller Capital Management first reported a position in AVEO in Q3 2019 and held it in 2 quarters. The position peaked at $11K in Q1 2021. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

  • Rockefeller Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,600 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $11K.
  • Rockefeller Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2019 and held it in 2 quarters.
  • Rockefeller Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $11K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Rockefeller Capital Management's 13F filing for Q2 2021, filed 10 Aug 2021.